Iran’s pharmaceutical companies have been facing production issues due to the US-imposed sanctions that have hindered the ability to buy raw material from third countries. Footage from Tehran on Tuesday, shows the way sanctions have affected the production process of one the largest Iranian drug companies Tolid Darou Pharmaceutical Company based in the Iranian capital. According to Research... Еще and Development Director Majid Sheykha, the company has been able to «moderate» the impact of the sanctions. «However, there are some fields that have been facing problems somehow, such as providing primary materials used for packaging and this is because we have faced problems regarding money transfer.» «We have lots of problem regarding providing the raw material,» explains Masoud Karbasiyan, manager at the company. For Masoud, despite the US President Donald Trump promising that the sanctions will not affect the people, the banking sanctions hinder the company’s ability to manufacture medication for the people of Iran. The US reinstated all the sanctions it had previously lifted as part of the Joint Comprehensive Plan of Action (JCPOA), also known as the Iranian nuclear deal. The sanctions target Iran's oil, banking and shipping industries and the Trump administration has also promised to institute harsh penalties for any other states that continue to conduct trade with the country.